ATE550345T1 - Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren - Google Patents

Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren

Info

Publication number
ATE550345T1
ATE550345T1 AT02707454T AT02707454T ATE550345T1 AT E550345 T1 ATE550345 T1 AT E550345T1 AT 02707454 T AT02707454 T AT 02707454T AT 02707454 T AT02707454 T AT 02707454T AT E550345 T1 ATE550345 T1 AT E550345T1
Authority
AT
Austria
Prior art keywords
sfrp
methods
interacting peptide
motif
peptide motives
Prior art date
Application number
AT02707454T
Other languages
German (de)
English (en)
Inventor
Jeffrey Rubin
Aykut Uren
Nicole Horwood
Matthew Gillespie
Brian Kay
Bernard Weisblum
Original Assignee
Us Health
St Vincents Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, St Vincents Inst Med Res filed Critical Us Health
Application granted granted Critical
Publication of ATE550345T1 publication Critical patent/ATE550345T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0643Osteoclasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/415Wnt; Frizzeled
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
AT02707454T 2001-01-10 2002-01-10 Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren ATE550345T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26090801P 2001-01-10 2001-01-10
PCT/US2002/000869 WO2002055547A2 (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use

Publications (1)

Publication Number Publication Date
ATE550345T1 true ATE550345T1 (de) 2012-04-15

Family

ID=22991151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02707454T ATE550345T1 (de) 2001-01-10 2002-01-10 Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren

Country Status (11)

Country Link
US (2) US7488710B2 (cg-RX-API-DMAC7.html)
EP (1) EP1387854B1 (cg-RX-API-DMAC7.html)
JP (3) JP4029041B2 (cg-RX-API-DMAC7.html)
AT (1) ATE550345T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002241859B2 (cg-RX-API-DMAC7.html)
CA (1) CA2434672C (cg-RX-API-DMAC7.html)
CY (1) CY1112875T1 (cg-RX-API-DMAC7.html)
DK (1) DK1387854T3 (cg-RX-API-DMAC7.html)
ES (1) ES2385666T3 (cg-RX-API-DMAC7.html)
PT (1) PT1387854E (cg-RX-API-DMAC7.html)
WO (1) WO2002055547A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094187A2 (ja) 2004-03-31 2005-10-13 Kazuo Shinya ラベル用物質とキメラ物質、これらの物質の作製方法、並びに該ラベル用物質を用いて生体物質を捕捉、構造解析又は/及び同定する方法
CN101124243A (zh) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
WO2008061029A1 (en) * 2006-11-10 2008-05-22 Wyeth Aryl sulfonamide derivatives and methods of their use
CN102014967A (zh) * 2008-03-21 2011-04-13 阿德利夫股份有限公司 芘携带肽穿过血脑屏障的用途
NZ605169A (en) * 2008-05-16 2014-11-28 Siebte Pmi Verwaltungs Gmbh Oilseed protein concentrates and isolates, and processes for the production thereof
JP2013006783A (ja) * 2011-06-22 2013-01-10 Nagasaki Univ 荷重感知遺伝子
PT3116521T (pt) * 2014-03-14 2024-10-15 Univ New York State Res Found Regulação neurogénica de crescimento ósseo e degradação óssea
PL3139979T3 (pl) 2014-05-07 2023-12-27 Boehringer Ingelheim International Gmbh Jednostka, nebulizator i sposób
US12344886B2 (en) * 2017-06-15 2025-07-01 Technion Research & Development Foundation Limited Compositions and methods for detection of genomic variations
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238839A (en) 1988-02-09 1993-08-24 Dana Farber Cancer Institute Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
AU3141693A (en) 1991-11-22 1993-06-15 Friedman, Mark M. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5726156A (en) 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
AU2664797A (en) 1996-04-12 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Wnt receptor compositions and methods
US5851984A (en) 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
WO1998013493A2 (en) 1996-09-24 1998-04-02 Lxr Biotechnology, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
NZ500253A (en) 1997-04-16 2002-09-27 Amgen Inc Osteoprotegerin binding proteins and receptors
US6043053A (en) 1997-05-23 2000-03-28 Smithkline Beecham Corporation Wnt-3 polynucleotides
US6479255B1 (en) 1997-05-29 2002-11-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polynucleotides encoding human FRP and fragments thereof
WO1999009152A1 (en) 1997-08-12 1999-02-25 Human Genome Sciences, Inc. Human frezzled-like protein
AU1535899A (en) 1997-11-25 1999-06-15 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11196864A (ja) 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
US6110718A (en) * 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
CZ2002903A3 (cs) * 1999-09-13 2002-07-17 American Home Products Corporation Farmaceutický prostředek s obsahem sekrenovaných proteinů příbuzných s proteiny frizzled
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
JP2002181893A (ja) * 2000-12-11 2002-06-26 Mitsubishi Electric Corp 半導体装置の検査方法および検査装置

Also Published As

Publication number Publication date
JP4248583B2 (ja) 2009-04-02
US20040077828A1 (en) 2004-04-22
JP2009005704A (ja) 2009-01-15
US8334260B2 (en) 2012-12-18
CA2434672A1 (en) 2002-07-18
AU2002241859B2 (en) 2007-07-19
EP1387854A2 (en) 2004-02-11
ES2385666T3 (es) 2012-07-30
JP4029041B2 (ja) 2008-01-09
WO2002055547A3 (en) 2003-11-20
WO2002055547A9 (en) 2002-10-31
WO2002055547A2 (en) 2002-07-18
US20080145884A1 (en) 2008-06-19
EP1387854B1 (en) 2012-03-21
JP2007300920A (ja) 2007-11-22
PT1387854E (pt) 2012-06-26
DK1387854T3 (da) 2012-07-09
JP4248600B2 (ja) 2009-04-02
CY1112875T1 (el) 2016-04-13
US7488710B2 (en) 2009-02-10
CA2434672C (en) 2014-03-25
JP2005501508A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
ATE522609T1 (de) Neurotrophe faktoren
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
DE69120390D1 (de) Kollagen-bindendes protein sowie dessen herstellung
SE9602822D0 (sv) New receptor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
SE0101519D0 (sv) Nucleic ACID
SE9604439D0 (sv) New receptor
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
WO2000037634A3 (en) Novel polypeptides and nucleic acids encoding same
TW200635951A (en) Specific binding agents of human angiopoietin-2